Abstract
Sigma receptors are classified into sigma1 and sigma2 subtypes. These subtypes display a different tissue distribution and a distinct physiological and pharmacological profile in the central and peripheral nervous system. The characterization of these subtypes and the discovery of new specific sigma receptor ligands demonstrated that sigma receptors are novel targets for the therapeutic treatment of neuropsychiatric diseases (schizophrenia, depression, and cognition), brain ischemia, and cocaine addiction. Furthermore, imaging of sigma1 receptors in the human brain using specific PET radioligands has started. In addition, the two sigma receptor subtypes are also expressed on tumor cells, where they could be of prognostic relevance. The ability of sigma2 receptor agonists to inhibit tumor cell proliferation through mechanisms that might involve apoptosis, intracellular Ca2+, and sphingolipids has promoted the development of sigma2 receptor agonists as novel therapeutic drugs for treating cancer. Consequently, sigma2 receptor ligands have been demonstrated to be potentially useful tumor imaging ligands. In this article, we focus on the sigma receptor ligands as therapeutic agents and as radiopharmaceuticals.
Keywords: CNS, NMDA receptor, antidepressants, 4-phenyl-1-(4-phenylbutyl)-piperidine (PPBP), ischemia, Cocaine addiction
Current Pharmaceutical Design
Title: Sigma Receptor Ligands: Possible Application as Therapeutic Drugs and as Radiopharmaceuticals
Volume: 12 Issue: 30
Author(s): Kiichi Ishiwata and Kenji Hashimoto
Affiliation:
Keywords: CNS, NMDA receptor, antidepressants, 4-phenyl-1-(4-phenylbutyl)-piperidine (PPBP), ischemia, Cocaine addiction
Abstract: Sigma receptors are classified into sigma1 and sigma2 subtypes. These subtypes display a different tissue distribution and a distinct physiological and pharmacological profile in the central and peripheral nervous system. The characterization of these subtypes and the discovery of new specific sigma receptor ligands demonstrated that sigma receptors are novel targets for the therapeutic treatment of neuropsychiatric diseases (schizophrenia, depression, and cognition), brain ischemia, and cocaine addiction. Furthermore, imaging of sigma1 receptors in the human brain using specific PET radioligands has started. In addition, the two sigma receptor subtypes are also expressed on tumor cells, where they could be of prognostic relevance. The ability of sigma2 receptor agonists to inhibit tumor cell proliferation through mechanisms that might involve apoptosis, intracellular Ca2+, and sphingolipids has promoted the development of sigma2 receptor agonists as novel therapeutic drugs for treating cancer. Consequently, sigma2 receptor ligands have been demonstrated to be potentially useful tumor imaging ligands. In this article, we focus on the sigma receptor ligands as therapeutic agents and as radiopharmaceuticals.
Export Options
About this article
Cite this article as:
Ishiwata Kiichi and Hashimoto Kenji, Sigma Receptor Ligands: Possible Application as Therapeutic Drugs and as Radiopharmaceuticals, Current Pharmaceutical Design 2006; 12 (30) . https://dx.doi.org/10.2174/138161206778559614
DOI https://dx.doi.org/10.2174/138161206778559614 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Ubiquitin Carboxyl Hydrolase L1 Significance for Human Diseases
Protein & Peptide Letters Metabolism of Drugs Used in the Therapy of Seizures: An Analytical Point of View. Part 1
Current Drug Metabolism Trypsin-Chymotrypsin Inhibitors from Vigna mungo Seeds
Protein & Peptide Letters Multi-targeting Strategies for Alzheimer's Disease Therapeutics: Pros and Cons
Current Topics in Medicinal Chemistry Hyperphosphorylation of Microtubule-Associated Protein Tau: A Promising Therapeutic Target for Alzheimer Disease
Current Medicinal Chemistry Neuropeptides as Therapeutic Targets to Combat Stress-Associated Behavioral and Neuroendocrinological Effects
CNS & Neurological Disorders - Drug Targets The Impact of Nandrolone Decanoate on the Central Nervous System
Current Neuropharmacology Hyperpolarized Metabolic MR in the Study of Cardiac Function and Disease
Current Pharmaceutical Design Pharmacogenetics of Alcohol and Alcohol Dependence Treatment
Current Pharmaceutical Design Neuropharmacological Properties of Withania somnifera - Indian Ginseng: An Overview on Experimental Evidence with Emphasis on Clinical Trials and Patents
Recent Patents on CNS Drug Discovery (Discontinued) Diversity of Human Immune System Multigene Families and its Implication in the Genetic Background of Rheumatic Diseases
Current Medicinal Chemistry Effects of Psychoactive Substances in Schizophrenia – Findings of Structural and Functional Neuroimaging
Current Topics in Medicinal Chemistry Reactive Oxygen Species Formation by Polymorphonuclear Cells and Mononuclear Cells as a Risk Factor of Cardiovascular Diseases
Current Pharmaceutical Biotechnology Positron Emission Tomography and Brain Monoamine Neurotransmission - Entries for Study of Drug Interactions
Current Pharmaceutical Design An Overview of Notch Signaling in Adult Tissue Renewal and Maintenance
Current Alzheimer Research Computational Models and Methods for Drug Target Prediction and Drug Repositioning
Combinatorial Chemistry & High Throughput Screening Decoding Corticotropin-Releasing Factor Receptor Type 1 Crystal Structures
Current Molecular Pharmacology Agonists at the a4b2 Nicotinic Acetylcholine Receptors Relationships and Molecular Modelling
Current Medicinal Chemistry Editorial (New Developments on NUCB2/Nesfatin-1)
Current Pharmaceutical Design